scispace - formally typeset
D

David A. Jackson

Researcher at King's College London

Publications -  1166
Citations -  76015

David A. Jackson is an academic researcher from King's College London. The author has contributed to research in topics: Optical fiber & Interferometry. The author has an hindex of 136, co-authored 1095 publications receiving 68352 citations. Previous affiliations of David A. Jackson include University of California, Berkeley & University of Alberta.

Papers
More filters
Journal ArticleDOI

Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.

TL;DR: The data presented suggest that covalent modification of proteins by LY293111 acyl glucuronide is possible in multiple species, although the relative reactivity of this metabolite appears to be low compared with those known to cause adverse drug reactions.
Proceedings ArticleDOI

Interferometric Strain Measurement Using Optical Fibres

TL;DR: In this paper, a fiber optic sensor for the measurement of strain is described, in which both the measurand induced changes in phase and polarisation state are simultaneously recovered, and a sensor with inherently great resolution and wide measurement range is thus realized.
Journal ArticleDOI

Note on the squared multiple correlation as a lower bound to communality

TL;DR: The authors showed that the squared multiple correlation of a variable with the remaining variables in a set of variables is a function of the communalities and the squared canonical correlations between the observed variables and common factors.
Journal ArticleDOI

Enhanced security in a coherence modulation system using optical path difference corruption

TL;DR: In this paper, a secure alternative method based on the corruption of the interferometers optical path difference is presented, which can be used for decoding the signal without any decoder interferometer.
Journal ArticleDOI

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

TL;DR: It is argued that molecular expansion of adverse event data may provide a path to improving the insights gained through more traditional pharmacovigilance approaches, and provides an elegant way to extend mechanistic modeling, systems pharmacology, and patient‐centered approaches for the assessment of drug safety.